spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  DPN 

 HSMN NewsFeed - 26 Jan 2023
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
Devices Neurology FDA
 HSMN NewsFeed - 13 Sep 2016
Aptinyx Receives FDA Fast Track Designation for Development of NYX-2925 as Treatment for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 Sep 2015
Depomed Files New Patent Infringement Lawsuit Against NUCYNTA(R) ER ANDA Filer
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 13 Apr 2015
Depomed Announces Gralise(R) ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing Appeal
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 24 Jun 2014
NeuroMetrix Reports Japan Regulatory Approval for NC-stat DPNCheck
Devices Regulatory
 HSMN NewsFeed - 5 May 2014
Immune Pharmaceuticals Announces Phase 3 Development and Commercialization Strategy for AMIKET
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2014
NeuroMetrix Announces Broad SENSUS Distribution Agreement with DJO Global
Devices Distribution
 HSMN NewsFeed - 19 Dec 2013
Celator(R) Pharmaceuticals Appoints Joseph M. Lobacki to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Dec 2013
Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jul 2013
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jan 2013
Celator(R) Pharmaceuticals Announces Appointment of Lisa DeLuca as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Dec 2012
Celator(R) Pharmaceuticals Announces Appointment of Fred Powell as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Nov 2012
NeuroMetrix Completes 510(k) Clearance Process for SENSUS(TM) Pain Management System
Devices Endocrinology Neurology FDA
 HSMN NewsFeed - 1 Nov 2012
NeuroMetrix Announces Distribution Agreement with OneSource Medical Group for SENSUS Pain Management Device
Devices Endocrinology Distribution
 HSMN NewsFeed - 4 May 2012
Pfizer Reports Top-Line Results From Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy
Biopharmaceuticals
 HSMN NewsFeed - 18 Apr 2012
NeuroMetrix Files 510(k) for SENSUS(TM) Pain Therapy Device
Devices Neurology FDA
 HSMN NewsFeed - 10 Jan 2011
Celator(R) Pharmaceuticals and Cephalon, Inc. Agree to Extend Research Agreement into Next Phase of Development
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Sep 2010
Celator(R) Pharmaceuticals Raises $20 Million in Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 May 2010
AVANIR Pharmaceuticals Announces Hiring of Michael McFadden as Vice President of U.S. Sales and Managed Markets
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 16 Jun 2008
FDA Approves Cymbalta(R) for the Management of Fibromyalgia
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 May 2008
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Biopharmaceuticals
 HSMN NewsFeed - 9 Apr 2008
Pfizer Statement on Exubera Labeling Update in the United States
Biopharmaceuticals Endocrinology Oncology
 HSMN NewsFeed - 7 Feb 2008
EpiCept Announces Encouraging Results of Phase II Trial for NP-1 Cream in Diabetic Peripheral Neuropathy
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
AVANIR Granted Special Protocol Assessment (SPA) From FDA for Confirmatory Phase III Trial of Zenvia in Patients With PBA
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Aug 2007
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
Biopharmaceuticals
 HSMN NewsFeed - 6 Aug 2007
AVANIR Pharmaceuticals Completes Sale Of FazaClo
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 23 Jul 2007
EpiCept Announces Phase III Study of EpiCept(TM) NP-1 for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Biopharmaceuticals
 HSMN NewsFeed - 3 Jul 2007
AVANIR Pharmaceuticals Announces Sale of FazaClo to Fund Continued Development of Zenvia
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2007
AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2007
AVANIR Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2007
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
Biopharmaceuticals
 HSMN NewsFeed - 3 May 2007
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2007
EpiCept Initiates Two Phase IIb Trials with NP-1
Biopharmaceuticals
 HSMN NewsFeed - 26 Feb 2007
FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 8

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 8 additional stories matching:
DPN
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!